Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis
Synergy With Tumor Necrosis Factor Blockade

Kazuyo Kaneko,1 Richard O. Williams,1 Daniel T. Dransfield,2 Andrew E. Nixon,2 Ann Sandison,3 and Yoshifumi Itoh1

Objective. In rheumatoid arthritis (RA), destruction of articular cartilage by the inflamed synovium is considered to be driven by increased activities of proteolytic enzymes, including matrix metalloproteinases (MMPs). The purpose of this study was to investigate the therapeutic potential of selective inhibition of membrane type 1 MMP (MT1-MMP) and its combination with tumor necrosis factor (TNF) blockage in mice with collagen-induced arthritis (CIA).

Methods. CIA was induced in DBA/1 mice by immunization with bovine type II collagen. From the onset of clinical arthritis, mice were treated with MT1-MMP selective inhibitory antibody DX-2400 and/or TNFR-Fc fusion protein. Disease progression was monitored daily, and serum, lymph nodes, and affected paws were collected at the end of the study for cytokine and histologic analyses. For in vitro analysis, bone marrow–derived macrophages were stimulated with lipopolysaccharide for 24 hours in the presence of DX-2400 and/or TNFR-Fc to analyze cytokine production and phenotype.

Results. DX-2400 treatment significantly reduced cartilage degradation and disease progression in mice with CIA. Importantly, when combined with TNF blockade, DX-2400 acted synergistically, inducing long-term benefit. DX-2400 also inhibited the up-regulation of interleukin-12 (IL-12)/IL-23 p40 via polarization toward an M2 phenotype in bone marrow–derived macrophages. Increased production of IL-17 induced by anti-TNF, which correlated with an incomplete response to anti-TNF, was abrogated by combined treatment with DX-2400 in CIA.

Conclusion. Targeting MT1-MMP provides a potential strategy for joint protection, and its combination with TNF blockade may be particularly beneficial in RA patients with an inadequate response to anti-TNF therapy.

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by progressive infiltration of the joints by leukocytes, production of mediators of inflammation, and the eventual destruction of joints, including the cartilage and bone (1). The introduction of tumor necrosis factor (TNF) inhibitors has greatly improved the management of RA. However, there remains a need to develop more effective and longer-lasting treatments for RA because a proportion of patients fail to respond to TNF inhibitors or their responsiveness is lost over time (2,3). Approaches combining a TNF inhibitor and other approved biologic agents that target different immunomodulatory pathways, such as CTLA-4 and interleukin-1 (IL-1), have shown no added efficacy but an increased risk of serious infections has been reported (4,5), suggesting that it is important to identify a new combination partner that...
improves response to anti-TNF therapy without increasing the risk of side effects.

During the progression of RA, the synovium becomes hyperplastic and locally invasive (commonly known as pannus), penetrating the surface of the cartilage and degrading its extracellular matrix (6). The cartilage extracellular matrix is primarily composed of fibrillar type II collagen and proteoglycan aggrecan, the degradation of which by pannus is associated with increased activity of proteolytic enzymes, including matrix metalloproteinases (MMPs) and aggrecanases (7). Early aggrecanase-mediated loss of aggrecan from cartilage can be reversed, but after the induction of MMP-mediated breakdown of collagen, cartilage damage becomes irreversible and leads to joint dysfunction (8). Thus, collagen degradation by MMPs is thought to be a critical step in the progression of joint damage.

The RA synovium consists of 2 major resident cell types, macrophage-like synoviocytes and fibroblast-like synoviocytes (FLS), along with recruited inflammatory cells, such as T cells, macrophages, B cells, dendritic cells, and mast cells (9). Among these cells, FLS and macrophages are the major sources of MMPs. FLS activated through cellular interactions and soluble factors produce MMP-1, MMP-2, MMP-13, and membrane type 1 MMP (MT1-MMP; also known as MMP-14), which can degrade type II collagen. Macrophages also produce MMP-1, MMP-2, and MT1-MMP (7,10). However, the precise functions of these MMPs in cartilage degradation remain elusive. The failure of broad-spectrum MMP inhibitors in clinical trials of cancer and RA (11) emphasizes the importance of targeting specific enzymes.

Among these collagenolytic MMPs, MT1-MMP is a type I transmembrane proteinase that is expressed on the cell surface and the only collagenase that directly promotes cellular invasion into 3-dimensional collagen matrices (12). Our previous work showed that MT1-MMP is highly expressed in FLS and macrophages at the cartilage–pannus junction in the joints of patients with RA and promotes the invasion of RA FLS into cartilage in vitro (13). Similar results were obtained by Sabeh et al (14), who demonstrated that silencing MT1-MMP, but not MMP-1, MMP-2, or MMP-13, inhibited cartilage invasion by RA synoviocytes (14). The findings of these studies suggest that MT1-MMP is a key enzyme in cartilage invasion by pannus in RA.

We used the collagen-induced arthritis (CIA) mouse model in the present study to determine whether MT1-MMP is a potential therapeutic target for joint damage in RA. We demonstrated that selective inhibition of MT1-MMP protects joints from cartilage damage and disease progression and enhances the response to anti-TNF treatment in established CIA.

PATIENTS AND METHODS

Collagen-induced arthritis. CIA was induced in male DBA/1 mice (11–13 weeks old) by immunization with bovine type II collagen, as previously described (15). From the onset of clinical arthritis, mice were treated intraperitoneally with either IgG isotype control, anti–MT1-MMP inhibitory antibody DX-2400 (20 or 40 mg/kg), TNFR-Fc fusion protein (2 or 8 mg/kg), or a combination of DX-2400 (20 mg/kg) and TNFR-Fc (2 mg/kg) every other day for 10 days. DX-2400 and IgG isotype control are recombinant human IgG1 expressed in Chinese hamster ovary cells as described previously (16). TNFR-Fc (etanercept) was obtained from the hospital pharmacy.

To avoid cage effects, treatment groups were randomized between cages. As individual mice developed clinical arthritis, they were assigned to different treatment groups in a sequential manner, irrespective of their cage. For long-term withdrawal studies, mice were treated for the first 5 days, and disease progression was monitored for 20 days after arthritis onset. Mice were monitored daily for arthritis. Paw thickness was measured with calipers. Visual assessment of arthritis severity was performed in a non-blinded manner and scored on a scale of 0–3, where 0 = normal, 1 = slight swelling and/or erythema, 2 = pronounced swelling, and 3 = ankylosis. All 4 limbs were scored, and the results were summed, giving a maximum score of 12. Serum and paw samples were collected at the end of the study. We confirmed that injection of control IgG had a negligible effect on disease severity as compared with that in untreated mice.

All experimental procedures were approved by the local Ethics Review Process Committee and the UK Home Office.

Histologic assessment of joints. At the end of study, the first affected paws were harvested, fixed in 10% neutral buffered formalin, and then decalcified in 10% EDTA for 3 weeks before standard processing for paraffin embedding. Sections (5 μm) were cut and stained with Safranin O for microscopic evaluation of the tarsometatarsal joints, which was performed in a blinded manner. Cartilage thickness was measured at 140-μm intervals using ImageJ software (National Institutes of Health) and calculated by averaging at least 10 measurements per image. Bone erosion was defined as demarcated defects in cartilage or bone associated with pannus invasion and was scored visually on a scale of 0–4, where 0 = none, 1 = minimal (1–2 sites of surface erosion), 2 = mild (at least 3 sites of surface erosion), 3 = moderate (discrete foci of erosion), and 4 = marked (large erosions extending into the marrow space).

For immunostaining of MT1-MMP, sections were deparaffinized, rehydrated, and subjected to antigen retrieval in 0.1M citrate buffer (pH 6.0) overnight at 60°C. After blocking for 1 hour with 10% goat serum and 1% bovine serum albumin, the sections were incubated for 2 hours at room temperature with rabbit anti–MT1-MMP monoclonal antibody (1:250 dilution; Epitomics), followed by incubation for 1 hour at room temperature with biotinylated secondary antibody (1:300 dilution). Staining was visualized with the use of Vectastain ABC kits and diaminobenzidine substrate (Vector) according to the manufacturer’s instructions. Slides were subsequently counterstained with hematoxylin.

Cell culture. Human FLS were isolated from synovial tissues obtained from RA patients, as previously described (13). Inguinal lymph nodes from mice were excised 10 days after the onset of CIA. Cells were dissociated and cultured at a density...
of 2 × 10⁶ cells/ml in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 50 units/ml of penicillin/streptomycin, and 50 µM 2-mercaptoethanol. Cells were left unstimulated or were stimulated with 100 ng/ml of anti-CD3 monoclonal antibody (145-2C11; eBioscience), and supernatants were collected for cytokine analysis at 48 hours after stimulation.

For generation of bone marrow–derived macrophages (BMMs), bone marrow cells were flushed from the tibias and femurs of 7–12-week-old male DBA/1 mice. Erythrocytes were depleted using an Erythrocyte Lysing kit (R&D Systems), and the remaining cells were cultured in RPMI 1640 supplemented with 10% FBS, 50 units/ml of penicillin/streptomycin, and 50 µM 2-mercaptoethanol containing 50 ng/ml of macrophage colony-stimulating factor (PeproTech). The medium was changed on day 3. BMMs were harvested on day 6 using a nonenzymatic cell dissociation solution (Sigma-Aldrich) and were plated in a 96-well plate (5 × 10⁴ cells/well) or a 48-well plate (3 × 10⁵ cells/well). The next day, cells were treated with 10 nM DX-2400 and/or TNFR-Fc, with or without lipopolysaccharide (LPS; 1 ng/ml), and at 24 hours after treatment, supernatants and total RNA, which was extracted using an RNeasy kit (Qiagen), were collected.

**Isolation of CD4+ T cells and B cells.** Single-cell suspensions were prepared from the spleens of 7–12-week-old DBA/1 mice. After erythrocyte depletion, CD4+ T cells and B cells were purified by positive selection using magnetic beads (Dynabeads; Invitrogen) according to the manufacturer’s instructions. Isolated cells were subjected to RNA extraction using an RNeasy kit.

**Collagen film degradation assay.** Type I collagen thin films were prepared as previously described (13). FLS (1 × 10⁶ cells/well) were cultured for 4 days on collagen film in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS in the presence or absence of 100 or 500 nM DX-2400 or 10 µM GM6001 (Elastin Products). Cells were removed by treatment with trypsin–EDTA (Sigma-Aldrich), and the films were fixed with 3% paraformaldehyde and stained with Coomassie blue. Images were captured using a 20× objective lens.

---

**Figure 1.** Reduced progression of arthritis following selective inhibition of membrane type 1 matrix metalloproteinase (MT1-MMP) in mice with collagen-induced arthritis (CIA). A, Collagen film degradation by human rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) in the absence or presence of 100 nM or 500 nM DX-2400, 10 µM GM6001, or buffer (control). Clear, unstained areas indicate collagen degradation. B, Invasion of human RA FLS into the cartilage in the presence of buffer alone (control), 10 µM GM6001, or 100 nM or 500 nM DX-2400. Arrows show invading FLS. C, Immunostaining for MT1-MMP in the tarsometatarsal joints of a normal mouse and a mouse with CIA (10 days after arthritis onset). Bar = 200 µm. D, Clinical scores, paw swelling (first affected paw), and number of affected paws 10 days after the onset of arthritis in mice with CIA treated with IgG control or with 20 or 40 mg/kg of DX-2400. Arrows indicate injection times. For the clinical scores and paw swelling data, values are the mean ± SEM of 22–23 mice per group. For the number of affected paws, each symbol represents an individual mouse; horizontal lines with bars show the mean ± SEM of 22–23 mice per group. * = P < 0.05 for the indicated comparison or versus IgG control; ** = P < 0.01 versus IgG control. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39414/abstract
Cartilage invasion assay. Cartilage invasion assay was carried out as previously described (13). FLS were cultured for 4 weeks on bovine nasal cartilage explants in DMEM supplemented with 2% FBS in the presence or absence of 100 or 500 nM DX-2400 or 10 μM GM6001. Cartilage explants were then fixed in 4% formalin and embedded in paraffin. Sections were cut at 5 μm and stained with mouse anti–MT1-MMP monoclonal antibody (222-1D8; Daiichi Fine Chemical Company), followed by counterstaining with hematoxylin.

Measurement of cytokine and cartilage oligomeric matrix protein (COMP). IL-17, interferon-γ (IFNγ), and IL-10 were measured using DuoSet enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems). For measurement of IL-12/IL-23 p40, we used an IL-12/IL-23 total p40 ELISA kit (eBioscience). Serum COMP levels were determined using an animal COMP ELISA kit (AnaMar).

Real-time reverse transcription–polymerase chain reaction (RT-PCR). Total RNA was reverse transcribed into complementary DNA (cDNA) using a high-capacity cDNA reverse transcription kit (Invitrogen) according to the manufacturer’s instructions. Messenger RNA (mRNA) expression levels were analyzed by real-time RT-PCR using the following TaqMan probes: Mm00485054_m1 for MT1-MMP, Mm00440502_m1 for type 2 nitric oxide synthase (NOS2), and Mm00475988_m1 for arginase 1. GAPDH served as an endogenous control.

Statistical analysis. Comparisons between 2 groups were performed using an unpaired 2-tailed t-test. For experiments involving multiple groups, one-way analysis of variance (ANOVA) followed by Turkey’s multiple comparison test was used, except for analysis of clinical scores and paw thicknesses, which used two-way ANOVA followed by Dunnett’s multiple comparison test. Calculations were made using GraphPad Prism 6 software. P values less than 0.05 were considered significant.

RESULTS
Selective inhibition of MT1-MMP and amelioration of CIA. Selective inhibition of MT1-MMP by an MT1-MMP inhibitory antibody, DX-2400, markedly inhibited the degradation of collagen film and the cartilage invasion by human RA FLS in a dose-dependent manner (Figures 1A

Figure 2. Prevention of cartilage degradation following selective inhibition of membrane type 1 matrix metalloproteinase in mice with collagen-induced arthritis (CIA). A, Histologic analysis of a joint from a normal mouse and arthritic joints from mice with CIA treated for 10 days with IgG control or with 20 or 40 mg/kg of DX-2400. Images at the top are representative images of Safranin O–stained sections of the tarsometatarsal joints. Images at the bottom are higher-magnification views of the boxed areas in the images at the top. Bar = 200 μm. The mean cartilage thickness (bottom left) and bone erosion scores (bottom right) in the tarsometatarsal joints of mice from the same treatment groups are also shown (n = 22–23 mice per group). For the mean cartilage thickness, each symbol represents an individual mouse; horizontal lines with bars show the mean ± SEM. For the bone erosion scores, values are the mean ± SEM. *** = P < 0.001. B, Serum levels of cartilage oligomeric matrix protein (COMP) in normal mice and mice with CIA treated for 10 days with IgG control or with 20 or 40 mg/kg of DX-2400 (n = 22–23 mice per group). Each symbol represents an individual mouse; horizontal lines with bars show the mean ± SEM. * = P < 0.05.
and B). To assess the effect of DX-2400 on cartilage degradation in vivo, we examined mice with CIA, a widely used murine model of RA. MT1-MMP was highly expressed in the joints of mice with CIA, while negligible expression was observed in normal joints (Figure 1C). In general, CIA initially affected 1 paw and then progressed to affect other paws during the course of the disease. Treatment with DX-2400 moderately reduced the clinical score, principally by reducing the spread of the disease to unaffected joints, rather than by ameliorating the already affected joints (Figure 1D).

Despite the lack of effect of DX-2400 on swelling (Figure 1D), histologic analysis of the joints from the first affected paws (Figure 2A) showed that the higher dose of DX-2400 led to markedly better preservation of cartilage structure and significantly less degradation of cartilage as compared with the IgG control. This observation was supported by the fact that serum levels of COMP, a marker of cartilage destruction (17), were also significantly lower in this group as compared to the IgG control group (Figure 2B). However, DX-2400 treatment had minimal effect on bone erosion (Figure 2A).

Thus, selective inhibition of MT1-MMP effectively prevented cartilage degradation and arthritis progression but had minimal effects on swelling and bone erosion in joints with established arthritis.

Synergistic effects of combined inhibition of MT1-MMP and TNF. Since TNF plays an important role in joint inflammation (18) as well as osteoclast differentiation and activation (19,20), we next assessed whether the combination of DX-2400 and a TNF inhibitor (soluble TNFR-Fc) might provide an additive or synergistic effect in CIA. As shown in Figure 3, suboptimal dosing with TNFR-Fc (2 mg/kg) moderately but significantly reduced both the clinical score and paw swelling, which were further reduced by optimal dosing with TNFR-Fc (8 mg/kg). Suboptimal and optimal dosing has been established in previous studies (21,22). The combination of DX-2400 and TNFR-Fc profoundly reduced both the clinical score and paw swelling in a synergistic manner, and the effect was greater than optimal dosing with TNFR-Fc alone. Although arthritis progression was inhibited in all groups, the arthritis was completely resolved in 43% of mice given the combined
treatment, as compared to 4% and 13% of mice given DX-2400 and TNFR-Fc alone, respectively.

In terms of joint damage, cartilage degradation was significantly inhibited by treatment with TNFR-Fc alone in a dose-dependent manner, and this effect was synergistically enhanced when TNFR-Fc was combined with DX-2400 (Figure 4A). Serum COMP levels and bone erosion were also significantly reduced in the combined treatment group, but not in the groups receiving DX-2400 or TNFR-Fc alone (Figures 4A and B).

We also examined the effect on long-term disease progression of withdrawal of DX-2400 and TNFR-Fc. The results showed that in the combined treatment group, arthritis severity remained stable after stopping treatment and remained significantly lower than that in the IgG control group at least until 15 days after cessation of treatment, whereas with TNFR-Fc treatment alone, the disease relapsed shortly after stopping treatment and reached the control level (Figure 5A). Cartilage degradation was also significantly inhibited at 15 days after cessation of treatment in mice given combined treatment (Figure 5B).

**Influence of MT1-MMP on macrophage function.** Synergy between inhibition of MT1-MMP and TNF is of great interest because it suggests that an MT1-MMP inhibitor would be effective in anti-TNF nonresponders. Previous work in mice has shown that despite reduced arthritis severity, inhibition of TNF leads to an expansion of peripheral Th1/Th17 cells via up-regulation of the common p40 subunit of IL-12/IL-23 in
myeloid cells (23). Subsequent studies have shown that an increase in Th17/IL-17 and p40 levels correlates with an incomplete response to anti-TNF treatment in patients with RA (24,25). Since macrophages also express high levels of MT1-MMP (Figure 6A) and are the primary source of TNF (26,27), we examined whether DX-2400 could modulate cytokine production by macrophages in vitro. When BMMs were stimulated for 24 hours with LPS in the presence of DX-2400 and/or TNFR-Fc, DX-2400 was found to significantly reduce p40 production but increase IL-10 production regardless of the presence or absence of TNFR-Fc (Figure 6B). Without LPS stimulation, neither p40 nor IL-10 was detected (data not shown). The failure to obtain increased p40 production with TNFR-Fc treatment was possibly because its production reached a maximum level under LPS stimulation alone.

The cytokine production profile in macrophages depends on their phenotype; classically activated M1 macrophages express IL-12^{high}/IL-10^{low}, whereas alternatively activated M2 macrophages express IL-12^{low}/IL-10^{high} (28). Analysis of mRNA expression of M1 (NOS2) and M2 (arginase 1) markers in BMMs treated with LPS showed that DX-2400 significantly up-regulated arginase 1 expression, whereas TNFR-Fc significantly up-regulated NOS2 expression. With the combination of DX-2400 and TNFR-Fc, the TNFR-Fc–induced up-regulation of NOS2 expression was counteracted, but the arginase 1 expression remained significantly higher, albeit to a lesser extent than that with DX-2400 alone (Figure 6C). This suggests that DX-2400 could divert the polarization of macrophages toward the anti-inflammatory M2 phenotype, resulting in a reduction of p40 production.
Selective inhibition of MT1-MMP and abrogation of the anti-TNF–induced up-regulation of IL-17 and IFNγ. To determine whether the M1-to-M2 shift induced by DX-2400 in vitro had an additive effect on T cell activity in vivo, we next isolated lymph node cells from mice with CIA 10 days after the start of treatment and stimulated them with anti-CD3 to determine cytokine production. Consistent with previous reports (23,24,29), cells isolated from mice treated with TNFR-Fc alone produced more IL-17 and IFNγ and in a dose-dependent manner than did those treated with IgG control. Treatment with DX-2400 alone did not alter the production of
either IL-17 or IFNγ, but interestingly, the TNFR-Fc–induced increase in IL-17 and IFNγ was not seen when combined with DX-2400 (Figure 6D). A similar trend was observed after stimulation with type II collagen (data not shown). Additionally, there was a trend toward increased production of p40 in cells isolated from mice treated with TNFR-Fc alone, but not those treated with DX-2400 and TNFR-Fc (Figure 6D).

**DISCUSSION**

The present study demonstrated 2 important proteolytic roles of MT1-MMP in RA: destruction of cartilage in joints with established RA and migration of pathogenic cells to unaffected joints. The inhibition of joint damage is a major goal of RA therapy. However, some patients who achieved clinical remission still experience progression of joint damage (30). In addition, current therapy, including TNF inhibition, does not abrogate cartilage damage as much as it does bone erosion (31–33). Hence, targeting MT1-MMP could represent a therapeutically useful strategy for minimizing cartilage damage. Consistent with earlier studies indicating that FLS are primarily responsible for cartilage damage in RA (9), we found that expression of MT1-MMP was remarkably high in synovium and that selective inhibition of MT1-MMP prevented the invasion of FLS into the cartilage (Figure 1). This suggests that reducing synovial invasiveness is likely to be a mechanism by which MT1-MMP blockade inhibits cartilage damage. MT1-MMP expression was also detected in chondrocytes, but cartilage degradation around MT1-MMP–positive chondrocytes was not observed (Figure 1). Thus, at least in the experimental setting of the present study, the impact of MT1-MMP blockade in chondrocytes is likely to be minimal.

As well as joint damage, continuous spreading of disease is a key feature of RA, although the underlying mechanisms remain largely unknown. Infiltration of circulating inflammatory cells into unaffected joints has long been speculated to be a potential cause. Indeed, a recent study suggested that activated FLS may be able to migrate from an inflamed joint to distant unaffected joints, leading to cartilage degradation (34). Further studies are required to identify the cell types involved in MT1-MMP–mediated spreading of arthritis, but evidence suggests that migration of FLS and monocytes depends on MT1-MMP (13,35). It is therefore possible that these cells use MT1-MMP to migrate into unaffected joints.

In contrast to the clear protective effect on cartilage degradation, selective inhibition of MT1-MMP alone had minimal effects on bone erosion in established arthritis, despite MT1-MMP being highly expressed in osteoclasts (36). While it has been suggested that MT1-MMP functions in the migration and attachment of osteoclasts (37), cysteine protease cathepsin K appears to be the critical proteinase for osteoclastic collagen degradation (38), which may explain why inhibition of MT1-MMP is not sufficient to inhibit bone erosion. Our analysis is based on an observational scoring system, however, and a more detailed quantitative analysis of bone erosion, such as micro–computed tomographic imaging, will be needed to draw conclusions about the effect of selective inhibition of MT1-MMP in bone erosion.

The results of the present study revealed that combined inhibition of MT1-MMP and TNF synergistically inhibits not only joint damage, but also synovial inflammation. These effects were maintained after discontinuation of treatment (Figure 5). If applied to humans, this combined therapeutic approach could allow for a reduction in both the dosage and frequency of administration of TNF inhibitors and possibly the induction of drug-free remission, particularly in the early stages of RA. While further studies are required to elucidate the mechanisms involved, this synergistic effect is unlikely to be due to decreased levels of MT1-MMP, since neither TNF nor IL-1 directly affects the expression of MT1-MMP in FLS (Kaneko K, et al: unpublished observations). However, anti–TNF therapy can reduce the production of other MMPs, including MMP-1 and MMP-3 (7,39), which may contribute to the synergistic effect. It has also been reported that anti–TNF therapy inhibits the recruitment of lymphocytes and monocytes into inflamed joints (40). The additional inhibition of MT-1-MMP may lead to the blockage of a whole range of pathogenic cells from migrating into the joint, thus preventing the progression of arthritis.

In addition to the effect on cell migration and invasion, we unexpectedly found that anti–MT1-MMP antibody modifies cytokine production by macrophages toward an antiinflammatory profile, likely by driving polarization toward an M2 phenotype. How the blocking of MT1-MMP alters macrophage polarization remains to be elucidated, but the mechanism may be mediated through the noncatalytic properties of MT1-MMP, since neither TNF nor IL-1 directly affects the expression of MT1-MMP in FLS (Kaneko K, et al: unpublished observations). However, anti–TNF therapy inhibits not only joint damage, but also synovial inflammation. These effects were maintained after discontinuation of treatment (Figure 5). If applied to humans, this combined therapeutic approach could allow for a reduction in both the dosage and frequency of administration of TNF inhibitors and possibly the induction of drug-free remission, particularly in the early stages of RA. While further studies are required to elucidate the mechanisms involved, this synergistic effect is unlikely to be due to decreased levels of MT1-MMP, since neither TNF nor IL-1 directly affects the expression of MT1-MMP in FLS (Kaneko K, et al: unpublished observations). However, anti–TNF therapy can reduce the production of other MMPs, including MMP-1 and MMP-3 (7,39), which may contribute to the synergistic effect. It has also been reported that anti–TNF therapy inhibits the recruitment of lymphocytes and monocytes into inflamed joints (40). The additional inhibition of MT-1-MMP may lead to the blockage of a whole range of pathogenic cells from migrating into the joint, thus preventing the progression of arthritis.

In addition to the effect on cell migration and invasion, we unexpectedly found that anti–MT1-MMP antibody modifies cytokine production by macrophages toward an antiinflammatory profile, likely by driving polarization toward an M2 phenotype. How the blocking of MT1-MMP alters macrophage polarization remains to be elucidated, but the mechanism may be mediated through the noncatalytic properties of MT1-MMP, since neither the broad-spectrum small-molecule MMP inhibitor GM6001 nor tissue inhibitor of metalloproteinases 2 showed an effect similar to that of DX-2400 on macrophage polarization (data not shown). This is supported by recent evidence suggesting that MT1-MMP modulates cellular functions in a catalytic activity–dependent and –independent manner, such as through molecular interactions (41). The observed effects on macrophages were further extended in the CIA model, revealing that anti–MT1-MMP treatment abrogates an increase in IL-17 production in draining
lymph nodes following anti-TNF treatment. Whether this is indeed caused by reduced production of IL-12/IL-23p40 by macrophages needs further investigation, but the observation is clinically important since anti-MT1-MMP treatment could potentially be used as an alternative to IL-17 blockade to enhance the response to TNF inhibitors (42).

In conclusion, the findings presented herein suggest that MT1-MMP constitutes an attractive target by which to halt the progression of joint damage in RA and to improve treatment outcomes in these patients, especially in those with an inadequate response to anti-TNF therapy. Current developments in the RA include targeting cytokines or T or B lymphocyte subsets (43,44), and the potential benefits of combining TNF inhibitors with other therapeutic agents should be carefully weighed against the increased risk of infection. MT1-MMP blockade is promising, as it alters synovial cell behavior mediated through pathways different from those targeted by TNF inhibitors.

ACKNOWLEDGMENTS

We thank A. Bahal, A. Seedhar, and P. Singh for preparing the histologic sections and H. Nagase, G. Murphy, M. Feldmann, and M. Norval for critical reading of the manuscript.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Itoh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Kaneko, Williams, Itoh.

Acquisition of data. Kaneko, Dransfield, Nixon, Sandison.

Analysis and interpretation of data. Kaneko, Williams, Sandison, Itoh.

ADDITIONAL DISCLOSURES

Authors Dransfield and Nixon are employees of Dyax Corporation.

REFERENCES

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–108.

2. Lloyd S, Bujkiewicz S, Waiioo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-α therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010;49:2313–21.

3. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007;46:1153–6.

4. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412–9.

5. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228–34.

6. Dodge GR, Poole AR. Immunohistochemical detection and immunochromic analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989;83:647–61.

7. Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 2008;4:128–35.

8. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Søndergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008;10:R63.

9. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008;223:252–70.

10. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827–39.

11. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007;13:333–46.

12. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004;167:769–81.

13. Miller MC, Manning HB, Jain A, Troeberg L, Dudhia J, Essex D, et al. Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 2009;60:968–97.

14. Sabeh F, Fox D, Weiss SJ. Membrane-type 1 matrix metalloproteinase-dependent regulation of rheumatoid arthritis synoviocyte function. J Immunol 2010;184:6396–406.

15. Williams RO. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-α. In: Sioud M, editor. Target discovery and validation: reviews and protocols. Totowa (NJ): Humana Press; 2007. p. 265–84.

16. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517–26.

17. Larsson E, Erlandsson Harris H, Larsson A, Mansson B, Saxne T, Klareskog L. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology (Oxford) 2004;43:428–34.

18. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9:1245–50.

19. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002;30:340–6.

20. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858–64.

21. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784–8.

22. Williams RO, Ohrabey J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IGG fusion protein and combination with anti-CD4. Immunology 1995;84:433–9.

23. Notley CA, Inglis JJ, Alzabin S, McCann FE, McMeece KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491–7.

24. Alzabin S, Abraham SM, Maher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71:1741–8.
25. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 2011;13:R126.

26. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage–pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1999;34:1125–32.

27. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347–53.

28. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677–86.

29. Arets NE, De Knop KJ, Leysen J, Elbo DG, Brdts CH, Weyler JJ, et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 2010;49:2264–72.

30. Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012;71:681–6.

31. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.

32. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870–7.

33. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor–induced arthritic effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277–90.